These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 34329582)
1. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Palve V; Knezevic CE; Bejan DS; Luo Y; Li X; Novakova S; Welsh EA; Fang B; Kinose F; Haura EB; Monteiro AN; Koomen JM; Cohen MS; Lawrence HR; Rix U Cell Chem Biol; 2022 Feb; 29(2):202-214.e7. PubMed ID: 34329582 [TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
3. Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib. Challa S; Kraus WL Cell Chem Biol; 2022 Feb; 29(2):171-173. PubMed ID: 35180430 [TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293 [TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876 [TBL] [Abstract][Full Text] [Related]
6. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213 [TBL] [Abstract][Full Text] [Related]
7. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations. Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345 [TBL] [Abstract][Full Text] [Related]
8. DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [ Bowden GD; Stotz S; Kinzler J; Geibel C; Lämmerhofer M; Pichler BJ; Maurer A J Med Chem; 2021 Nov; 64(21):15690-15701. PubMed ID: 34672571 [TBL] [Abstract][Full Text] [Related]
9. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178 [TBL] [Abstract][Full Text] [Related]
10. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Laird JH; Lok BH; Ma J; Bell A; de Stanchina E; Poirier JT; Rudin CM Clin Cancer Res; 2018 Oct; 24(20):5143-5152. PubMed ID: 29945991 [No Abstract] [Full Text] [Related]
11. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088 [TBL] [Abstract][Full Text] [Related]
12. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813 [TBL] [Abstract][Full Text] [Related]
13. PARP Inhibitors in Ovarian Cancer. Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470 [TBL] [Abstract][Full Text] [Related]
14. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384 [TBL] [Abstract][Full Text] [Related]
15. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Herriott A; Tudhope SJ; Junge G; Rodrigues N; Patterson MJ; Woodhouse L; Lunec J; Hunter JE; Mulligan EA; Cole M; Allinson LM; Wallis JP; Marshall S; Wang E; Curtin NJ; Willmore E Oncotarget; 2015 Dec; 6(41):43978-91. PubMed ID: 26539646 [TBL] [Abstract][Full Text] [Related]
16. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019 [TBL] [Abstract][Full Text] [Related]
17. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812 [TBL] [Abstract][Full Text] [Related]
18. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1. Ryan K; Bolaňos B; Smith M; Palde PB; Cuenca PD; VanArsdale TL; Niessen S; Zhang L; Behenna D; Ornelas MA; Tran KT; Kaiser S; Lum L; Stewart A; Gajiwala KS J Biol Chem; 2021; 296():100251. PubMed ID: 33361107 [TBL] [Abstract][Full Text] [Related]
20. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. Ma L; Bian X; Lin W J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]